July 17, 2008 - GE Healthcare’s iodixanol, an isosmolar contrast medium, shows lower incidence of elevated serum creatinine (SCr) or decreased glomerular filtration rate (GFR) than iopromide, according to a study written by a team of physicians and researchers at the Medical University of South Carolina, and published in “Radiology”, a peer-reviewed journal for the field of radiology.

The study included 117 patients with decreased renal function, defined as SCr>1.5 mg/mL or GFR

Fewer patients administered iodixanol showed an SCr increase of 25 percent or greater, 8.5 percent vs. 28 percent respectively. No patients in either group showed a contrast media related adverse event at the 30- or 90-day follow-up. There was a clinically-relevant GFR reduction of 5mL/min in significantly more patients in the iopromide group than in the iodixanol group; 42.3 percent vs. 24.1 percent.
The study concluded that while intravenous contrast material application in high-risk patients is unlikely to be associated with permanent adverse outcomes, SCr levels after contrast material administration are lower in the iodixanol group than in the iopromide group.

The authors noted their findings may differ from other recently published studies on the topic. According to the text of the study, “Our [the authors] systematic serial assessment of SCr level and GFR over 3 days after CM [contrast media] administration may have been more sensitive to detect SCr-level changes compared with the single sampling at a variable interval (48-72 hours) after contrast medium administration in the prior investigation. Considering that in most patients with decreased renal function, the SCr will peak in the first 72 hours after CM administration, multiple measures may provide greater accuracy regarding SCr dynamics.”

“This study confirms the favorable safety profile of iodixanol in patients undergoing CT scans who may be at-risk for nephropathy,” said Richard Vitti, M.D., associate director medical & professional services in GE Healthcare.

For more information: www.gehealthcare.com, http://radiology.rsnajnls.org/


Related Content

News | Radiology Business

July 9, 2024 — Bracco and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time July 09, 2024
arrow
News | Contrast Media

May 8, 2024 — Swedish biotech company Ascelia Pharma AB has announced that its liver imaging drug candidate, Orviglance ...

Time May 08, 2024
arrow
News | FDA

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
News | Breast Imaging

March 8, 2024 — Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies ...

Time March 08, 2024
arrow
News | SNMMI

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
Feature | Contrast Media Injectors | By Christine Book

Contrast media injectors are used to inject contrast media or contrast agents to enhance the blood and perfusion in ...

Time January 17, 2024
arrow
News | Contrast Media

December 11, 2023 — Bracco Imaging S.p.A., an innovative world leader delivering end-to-end products and solutions ...

Time December 11, 2023
arrow
News | Interventional Radiology

November 3, 2023 — Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced ...

Time November 03, 2023
arrow
Subscribe Now